S6 Ep50: Tarantino Previews Exciting Research in HER2-Low Breast Cancer
OncLive® On Air - En podcast av OncLive® On Air
Dr Tarantino provides background on the categorization of HER2-low disease in breast cancer, issues with standardization and interpretation, historical management strategies, and ongoing research with agents including trastuzumab deruxtecan, trastuzumab duocarmazine, and disitamab vedotin.
